Skip to content

The Yangxuegufa lotion in the treatment of androgenic alopecia: safety, efficacy and mechanism

The Yangxuegufa lotion in the treatment of androgenic alopecia: safety, efficacy and mechanism

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002356
Enrollment
Unknown
Registered
2025-11-28
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

androgenetic alopecia

Interventions

Drug intervention group:Yangxuegufa lotion
Placebo control group:Placebo lotion

Sponsors

The Second Affiliated Hospital of Hunan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: a. Male or female patients aged 18 years or above. b. Meet the diagnostic criteria for androgenetic alopecia as defined by Western medicine; and belong to the mild/moderate category in the BASP classification, including types M1, M2, C1, V1, V2, F1, F2, and F3. c. Have a thorough understanding of the research purpose and a basic knowledge of the product's usage and possible adverse reactions. d. Have not used any oral drugs, topical medications, microneedling, mesoderm treatment, low-energy laser, or hair transplantation surgery for hair loss within the 6 months prior to enrollment. e. Be able to adhere to follow-up and provide true feedback. f. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: a. Congenital alopecia, scarring alopecia, lupus alopecia, syphilitic alopecia, alopecia areata, trichotillomania and other scarring alopecia. b. Having systemic infections or open wounds on the head. c. Having advanced psoriasis, atopic dermatitis, eczema, skin cancer, autoimmune diseases, severe systemic diseases and mental disorders that the researchers consider unsuitable for inclusion in the study. d. During pregnancy or lactation, or planning to get pregnant in the near future. e. Having a history of immunosuppression/immunological disorders (including HIV infection or AIDS). f. Known to be allergic to a certain component of the study drug, or having a history of other drug allergies. g. Planning to use or having used other treatment regimens for hair loss during the study period. h. Unable or unwilling to cooperate with the use of study drugs, undergoing examinations and tests, providing usage feedback, unable or unwilling to follow medical advice for medication and follow-up visits.

Design outcomes

Primary

MeasureTime frame
The total diameter of the hairs;

Secondary

MeasureTime frame
General appearance;Microscopic hair structure;The number of hairs per unit area (in units of roots);Average hair diameter (µm);Hair density (per cm2);Final hair density (per cm2);Final hair ratio (% );Hair follicle density (per cm2);Average hair count / Hair follicle unit count;The proportion of single hair follicles (%);Hair loss score;Pruritus score;

Countries

China

Contacts

Public ContactLong Di

The Second Affiliated Hospital of Hunan University of Chinese Medicine

longdi92@foxmail.com13873172470

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026